ecrin-mdr-crcClinical2010Prostatic NeoplasmsNeoplasm MetastasisMelanomaColorectal NeoplasmsNeoplasmsHead and Neck NeoplasmsProstatic NeoplasmsNeoplasm MetastasisMelanomaColorectal NeoplasmsHead And Neck NeoplasmsNeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2093934United States12ECRIN MDRCompletedfalseExploration of Tumor Accumulation of BAY94-9392 in Patients With CancerThe study will be conducted as an open label, single-dose, explorative study with patients with histologically proven cancer and, preferably, tumor positive lesions in previously performed nuclear medicine imaging examinations. The investigational drug will be given as a single administration in a dose of </= 0.1 mg BAY94-9392 (300 MBq, +/- 10%). The total duration of the study for each patient will be approximately 8 days.2010-12-152093934NCT01186601